| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
93,430,000 |
| Market
Cap: |
13.26(B) |
| Last
Volume: |
670,978 |
Avg
Vol: |
808,349 |
| 52
Week Range: |
$89.53 - $143.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 946 |
| Guru Rank Value : 0 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Neurocrine Biosciences is applying its capabilities into neuroscience to develop medicines for neurology, neuroendocrinology and neuropsychiatry-related disorders and diseases. Co.'s commercially available medicines include INGREZZA®, which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 mg, 60 mg and 80 mg capsules); and ONGENTYS®, which is a once-daily, peripherally acting Catechol-O-methyltransferase inhibitor utilized to prolong the duration of effect of levodopa, the primary treatment option for Parkinson's disease patients, during periods of the day where the effects of levodopa wear off and motor symptoms worsen.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
275,180 |
771,010 |
813,558 |
1,280,765 |
| Total Sell Value |
$37,779,030 |
$101,803,598 |
$106,435,205 |
$158,397,673 |
| Total People Sold |
5 |
15 |
15 |
17 |
| Total Sell Transactions |
17 |
70 |
85 |
154 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bozigian Haig P. |
Chief Development Officer |
• – – |
2019-05-13 |
4 |
OE |
$8.66 |
$299,177 |
D/D |
34,547 |
176,523 |
|
- |
|
| Grigoriadis Dimitri E. |
Chief Research Officer |
• – – |
2019-05-13 |
4 |
AS |
$75.44 |
$125,007 |
D/D |
(1,657) |
118,408 |
|
- |
|
| Cooke Julie |
Chief Human Resources OfficerO |
• – – |
2019-05-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,916 |
|
- |
|
| Gano Kyle |
Chief Business Development Off |
• – – |
2019-02-06 |
4 |
AS |
$83.56 |
$63,673 |
D/D |
(762) |
85,833 |
|
- |
|
| Grigoriadis Dimitri E. |
Chief Research Officer |
• – – |
2019-02-06 |
4 |
AS |
$84.03 |
$44,622 |
D/D |
(531) |
120,065 |
|
- |
|
| Lloyd-Smith Malcolm |
Chief Regulatory Officer |
• – – |
2019-02-06 |
4 |
AS |
$83.58 |
$76,894 |
D/D |
(920) |
19,238 |
|
- |
|
| Benevich Eric |
Chief Commercial Officer |
• – – |
2019-02-06 |
4 |
AS |
$83.57 |
$76,883 |
D/D |
(920) |
20,745 |
|
- |
|
| Lippoldt Darin |
Chief Legal Officer |
• – – |
2019-02-06 |
4 |
AS |
$83.52 |
$66,063 |
D/D |
(791) |
19,646 |
|
- |
|
| Gorman Kevin Charles |
Chief Executive Officer |
• • – |
2019-02-06 |
4 |
AS |
$84.23 |
$344,986 |
D/D |
(4,096) |
417,597 |
|
- |
|
| Bozigian Haig P. |
Chief Development Officer |
• – – |
2019-02-06 |
4 |
AS |
$83.54 |
$76,859 |
D/D |
(920) |
141,639 |
|
- |
|
| Gano Kyle |
Chief Business Development Off |
• – – |
2019-02-05 |
4 |
AS |
$88.05 |
$214,482 |
D/D |
(2,434) |
84,695 |
|
- |
|
| Grigoriadis Dimitri E. |
Chief Research Officer |
• – – |
2019-02-05 |
4 |
AS |
$88.17 |
$94,338 |
D/D |
(1,070) |
119,071 |
|
- |
|
| Benevich Eric |
Chief Commercial Officer |
• – – |
2019-02-05 |
4 |
AS |
$87.95 |
$119,427 |
D/D |
(1,357) |
19,015 |
|
- |
|
| Lippoldt Darin |
Chief Legal Officer |
• – – |
2019-02-05 |
4 |
AS |
$88.08 |
$107,911 |
D/D |
(1,225) |
18,162 |
|
- |
|
| Gorman Kevin Charles |
Chief Executive Officer |
• • – |
2019-02-05 |
4 |
AS |
$88.12 |
$395,895 |
D/D |
(4,489) |
413,943 |
|
- |
|
| Lloyd-Smith Malcolm |
Chief Regulatory Officer |
• – – |
2019-02-05 |
4 |
AS |
$88.13 |
$112,119 |
D/D |
(1,272) |
17,508 |
|
- |
|
| Bozigian Haig P. |
Chief Development Officer |
• – – |
2019-02-05 |
4 |
AS |
$88.06 |
$118,986 |
D/D |
(1,350) |
139,909 |
|
- |
|
| Gano Kyle |
Chief Business Development Off |
• – – |
2019-02-04 |
4 |
AS |
$88.14 |
$121,186 |
D/D |
(1,375) |
80,117 |
|
- |
|
| Grigoriadis Dimitri E. |
Chief Research Officer |
• – – |
2019-02-04 |
4 |
AS |
$88.12 |
$121,167 |
D/D |
(1,375) |
117,066 |
|
- |
|
| Gorman Kevin Charles |
Chief Executive Officer |
• • – |
2019-02-04 |
4 |
AS |
$88.10 |
$275,321 |
D/D |
(3,125) |
408,082 |
|
- |
|
| Bozigian Haig P. |
Chief Development Officer |
• – – |
2019-02-04 |
4 |
AS |
$88.10 |
$121,139 |
D/D |
(1,375) |
137,372 |
|
- |
|
| Roberts Eiry |
Chief Medical Officer |
• – – |
2019-01-08 |
4 |
AS |
$84.09 |
$156,159 |
D/D |
(1,857) |
3,143 |
|
- |
|
| Abernethy Matt |
Chief Financial Officer |
• – – |
2018-12-03 |
4 |
AS |
$90.00 |
$106,020 |
D/D |
(1,178) |
1,947 |
|
- |
|
| Pops Richard F |
Director |
– • – |
2018-11-26 |
4 |
AS |
$91.37 |
$376,790 |
D/D |
(4,124) |
29,512 |
|
- |
|
| Pops Richard F |
Director |
– • – |
2018-11-12 |
4 |
AS |
$103.30 |
$425,893 |
D/D |
(4,123) |
33,636 |
|
- |
|
807 Records found
|
|
Page 18 of 33 |
|
|
0.09 (0.06%) 
